It remains a cornerstone therapy for thrombotic thrombocytopenic purpura (TTP), where TPE removes large von Willebrand factor multimers that would otherwise bind platelets to form microthrombi, while also allowing the replacement of deficient ADAMTS13 protease through complementary recombinant protein infusions [10,11,12]. Here, VWF is linked to thrombotic thrombocytopenic purpura.